Status:
COMPLETED
A Study Evaluating the Addition of MabThera (Rituximab) to Standard Treatment in Patients With Idiopathic Thrombocytopenic Purpura (ITP)
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Idiopathic Thrombocytopenic Purpura
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This study will compare the efficacy, safety, and pharmacokinetics of standard treatment versus standard treatment plus MabThera in patients with ITP. The anticipated time on study treatment is \<3 mo...
Eligibility Criteria
Inclusion
- adult patients \>=18 years of age;
- untreated ITP.
Exclusion
- ITP with relapse;
- positive test result for HIV or hepatitis B or C;
- active infection requiring systemic therapy;
- malignancy within 3 years before study.
Key Trial Info
Start Date :
July 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2008
Estimated Enrollment :
103 Patients enrolled
Trial Details
Trial ID
NCT00770562
Start Date
July 1 2005
End Date
July 1 2008
Last Update
October 22 2014
Active Locations (22)
Enter a location and click search to find clinical trials sorted by distance.
1
Bari, Italy, 70124
2
Bologna, Italy, 40138
3
Brescia, Italy, 25123
4
Cagliari, Italy, 09121